Stock picks with research | support | resistance and technical analysis for trading | Day trading | stock investing in the market
day investing picks penny stock trading
Skip Navigation Links
    •   About US
    Market Activity
    World Indices
    Market Watch
    Customer Service
    Learning Center
    Economic Event

Join Now

stock Breakout for day trading

advertise 2 ۩  Daily market forecast
Stock : AMED |   Stock Recommendations : Buy
Sector : Healthcare |   First resistance : 65.08
Stock Name : AMEDISYS INC COM |   Second resistance : 67.29
Buy Near : 55.13 |   Third resistance :
StopLoss : 46.55 |   First Support : 55.03
Posted date : 11/2/2008 12:00:00 AM |   Second Support : 46.55

Amedisys Inc. com (AMED) Stock has given a buy signal, with rising moving average. Stockhastic and ADX also given a buy signal.

   Amedisys Inc. com (AMED) announced on 10/28/08 its profit grew 16 percent in the third quarter, and revenue jumped 78 percent. The company reported stronger admissions growth, and it was operating 150 more health agencies than a year earlier and also raised its full-year estimates, predicting greater profit and revenue Amedisys Inc. com (AMED) is a Home nursing company. As per technical analysis, Stock analysis and fundamentally this Stock looks good candidate for portfolio investment. Amedisys Inc. com Stock you can consider for Stock Market Investment, Swing Trading, Stock trading, Stock Investing, Day trading, Stock picks, Breakout Stocks. Due to Stock market and economic condition keep tight stop loss on all position. You can buy this Stock near $55.13

Portfolio stock

Recent News Head Lines
AMEDISYS Inc (AMED) Q4 2020 Earnings Call Transcript
(Fri, 26 Feb 2021 00:31:17 +0000)
AMED earnings call for the period ending December 31, 2020.
P/E Ratio Insights for Amedisys
(Thu, 25 Feb 2021 14:54:47 +0000)
Looking into the current session, Amedisys Inc. (NASDAQ:AMED) is trading at $275.15, after a 2.29% decrease. Over the past month, the stock decreased by 4.64%, but over the past year, it actually went up by 58.04%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently under from its 52 week high by 15.37%. The P/E ratio measures the current share price to the company's earnings per share. It is used by long-term investors to analyze the company's current performance against its past earnings, historical data and aggregate market data for the industry or the indices, such as S&P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also shows that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. View more earnings on AMED Most often, an industry will prevail in a particular phase of a business cycle, than other industries. Compared to the aggregate P/E ratio of 33.59 in the Health Care Providers & Services industry, Amedisys Inc. has a higher P/E ratio of 56.43. Shareholders might be inclined to think that Amedisys Inc. might perform better than its industry group. It's also possible that the stock is overvalued. There are many limitations to price to earnings ratio. It is sometimes difficult to determine the nature of the earnings makeup of a company. Shareholders might not get what they're looking for, from trailing earnings. See more from BenzingaClick here for options trades from BenzingaAmedisys: Q4 Earnings InsightsPreview: Amedisys's Earnings© 2021 Benzinga does not provide investment advice. All rights reserved.
Amedisys, Inc. to Host Earnings Call
(Thu, 25 Feb 2021 14:30:00 +0000)
NEW YORK, NY / ACCESSWIRE / February 25, 2021 / Amedisys, Inc. (NASDAQ:AMED) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 25, 2021 at 11:00 AM Eastern Time.
Amedisys: Q4 Earnings Insights
(Wed, 24 Feb 2021 22:32:55 +0000)
Shares of Amedisys (NASDAQ:AMED) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 58.51% over the past year to $1.49, which beat the estimate of $1.47. Revenue of $550,705,000 higher by 9.99% year over year, which missed the estimate of $553,370,000. Looking Ahead The upcoming fiscal year's EPS expected to be between $6.25 and $6.47. View more earnings on AMED The upcoming fiscal year's revenue expected to be between $2,275,000,000 and $2,315,000,000. Price Action 52-week high: $325.12 52-week low: $132.95 Price action over last quarter: Up 10.55% Company Overview Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patient's homes throughout the United States. The Hospice segment operates many centers designed to provide comfort and support for terminally ill patients. The Personal Care Segment provides individuals with assistance in the daily living activities. A majority of the company's revenue is derived from the Home Health segment. Additionally, the Hospice segment accounts for a substantial amount of revenue, while the Personal Care segment makes up for the small remaining revenue. See more from BenzingaClick here for options trades from BenzingaPreview: Amedisys's Earnings© 2021 Benzinga does not provide investment advice. All rights reserved.
Amedisys Announces Two Executive Promotions
(Wed, 24 Feb 2021 21:05:00 +0000)
Christopher Gerard named President and Chief Operating Officer and Scott Ginn named Executive Vice President and Chief Financial Officer BATON ROUGE, La., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and personal care, announces the promotions of Christopher Gerard, to President and Chief Operating Officer, and Scott Ginn, to Executive Vice President and Chief Financial Officer, effective immediately. Paul Kusserow continues his role as Chairman of the Board and Chief Executive Officer. “I am thrilled to announce the appointment by the Board of Directors of Chris Gerard to President and Chief Operating Officer, and Scott Ginn to Executive Vice President and Chief Financial Officer,” stated Chairman and CEO Paul Kusserow. “I have had the privilege of working with Scott since 2014 and Chris since 2017, and the performance of the Company under their leadership has been nothing short of tremendous. Both Chris and Scott bring incredible experience and expertise to our team, and have been key to setting the strategic direction and executing on that strategy to deliver superlative results. Both of these promotions are richly deserved and fully earned as a result of exemplary leadership and achievements. As they take on their new positions, I am confident that both will continue to lead Amedisys–with the support of our management team—to even greater levels of success.” During Gerard’s tenure as Chief Operating Officer, Amedisys has realized clinical and operational success and growth in all three business lines. Under his leadership, Amedisys has: grown its footprint to include 514 care centers which span 39 states and the District of Columbia; become the leader in Home Health quality achieving a Quality of Patient Care Star score of 4.33 stars with 95% of all care centers at 4 stars or above; prospered even with the implementation of the Patient-Driven Groupings Model, the largest payment reform from the Centers for Medicare and Medicaid Services (CMS) in 20 years; and become the third largest hospice provider in the United States. In his leadership roles at Amedisys, most recently as Chief Financial Officer, Ginn has been responsible for all accounting operations, mergers and acquisitions, innovations, cost control systems and financial reporting. He has played a pivotal role in leading financial operations and building strong relationships with our analysts, lenders and shareholders and in growing Amedisys’ revenue from $500 million to over $2 billion. “Amedisys’ vision to become the solution for those who want to age in place has never been more important than it is in today’s reality,” stated Chris Gerard, President and Chief Operating Officer. “I am excited and honored to help lead Amedisys with continued excellence. It’s gratifying to be a part of such an exceptional organization of wonderful caregivers who are committed to the highest quality of patient care.” “It has been a privilege to be a part of Amedisys for the past 14 years,” stated Scott Ginn, Executive Vice President and Chief Financial Officer. “It is rewarding to be a member of a team that helped our Company execute in all areas of our strategy. I’m excited about our opportunities in the future to continue to grow Amedisys which will allow us to provide our excellent clinical care to even more patients across the country.” About Amedisys: Amedisys, Inc. is a leading healthcare at home company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering patients to manage a chronic disease; or hospice care at the end of life. More than 2,900 hospitals and 78,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 21,000 employees, in 514 care centers in 39 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 418,000 patients and clients in need every year. For more information about the Company, please visit: Contact: Amedisys, Inc.Amedisys, Inc.Investor RelationsMedia

Never go against major trend for day trading | stock trading

Home for ۩ Day Trading | Breakout Stock trading system | Penny Stock Investing | Market Research

Contact Us | Affiliate | Disclaimer | Feedback | Help | Site Map | RSS  RSS
All Rights Reserved © 2000-2006
Chart courtesy of
Portfolio stock - AMEDISYS INC COM for Stock investing stock trading day trading

This Service is solely an information service provided by the automated software tool & is for entertainment purposes only. It should be understood that there is no guarantee that past performance of our stock trading system or day trading Strategy or Penny stock picks will be indicative of future results.